Investigational epigenetic therapy lowers incidence of MACE in phase 2b study - PACE-CME

Investigational epigenetic therapy lowers incidence of MACE in phase b study

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Exciting times to address residual inflammatory risk
Exciting times to address residual inflammatory risk
EAS 2024
Exciting times to address residual inflammatory risk
- Peter Libby, MD
Anti-inflammatory therapies for CVD risk prevention
Anti-inflammatory therapies for CVD risk prevention
EAS 2024
Anti-inflammatory therapies for CVD risk prevention
- Ulrich Laufs, MD, PhD
Pro/con debate: Are we ready to treat inflammation for ASCVD prevention?
Pro/con debate: Are we ready to treat inflammation for ASCVD prevention?
EAS 2024
Pro/con debate: Are we ready to treat inflammation for ASCVD prevention?
- Ulrich Laufs, MD, PhD
- Paul Ridker, MD
Lessons from a trial with colchicine in patients undergoing thoracic surgery
Lessons from a trial with colchicine in patients undergoing thoracic surgery
ESC Congress 2023
Lessons from a trial with colchicine in patients undergoing thoracic surgery
- Lukas Hoes, MD
- David Conen, MD